209 related articles for article (PubMed ID: 25702090)
1. Identification of potential erythrocyte phospholipid fatty acid biomarkers of advanced lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer.
Sánchez-Rodríguez P; Rodríguez MC; Sánchez-Yagüe J
Tumour Biol; 2015 Jul; 36(7):5687-98. PubMed ID: 25702090
[TBL] [Abstract][Full Text] [Related]
2. Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Sánchez-Rodríguez P; Sánchez-Yagüe J
Am J Clin Pathol; 2014 Jul; 142(1):111-20. PubMed ID: 24926094
[TBL] [Abstract][Full Text] [Related]
3. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
[TBL] [Abstract][Full Text] [Related]
4. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma.
De Castro J; Hernández-Hernández A; Rodríguez MC; Sardina JL; Llanillo M; Sánchez-Yagüe J
Platelets; 2007 Feb; 18(1):43-51. PubMed ID: 17365853
[TBL] [Abstract][Full Text] [Related]
5. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
7. Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Llanillo M; Sánchez-Yagüe J
Exp Mol Pathol; 2009 Dec; 87(3):226-33. PubMed ID: 19733167
[TBL] [Abstract][Full Text] [Related]
8. Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Puskas R; Bikov A; Horvath P; Lazar Z; Kunos L; Nagy R; Pinter G; Galffy G
Pathol Oncol Res; 2021; 27():631969. PubMed ID: 34257598
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.
Stumpf C; Kaemmerer D; Neubauer E; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1921-1932. PubMed ID: 30076481
[TBL] [Abstract][Full Text] [Related]
10. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
11. Serum free fatty acid biomarkers of lung cancer.
Liu J; Mazzone PJ; Cata JP; Kurz A; Bauer M; Mascha EJ; Sessler DI
Chest; 2014 Sep; 146(3):670-679. PubMed ID: 24743744
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
13. Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling.
Okano T; Seike M; Kuribayashi H; Soeno C; Ishii T; Kida K; Gemma A
Int J Oncol; 2016 Mar; 48(3):945-52. PubMed ID: 26783151
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma.
Qiu JF; Zhang KL; Zhang XJ; Hu YJ; Li P; Shang CZ; Wan JB
Lipids; 2015 Oct; 50(10):977-85. PubMed ID: 26294003
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
16. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling.
Hocker JR; Peyton MD; Lerner MR; Lightfoot SA; Hanas RJ; Brackett DJ; Hanas JS
Cancer Invest; 2012 Feb; 30(2):180-8. PubMed ID: 22149138
[TBL] [Abstract][Full Text] [Related]
18. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential serum biomarkers for simultaneously classifying lung adenocarcinoma, squamous cell carcinoma and small cell carcinoma.
Yu J; Du F; Yang L; Chen L; He Y; Geng R; Wu L; Xie B
Cancer Biomark; 2021; 30(3):331-342. PubMed ID: 33361584
[TBL] [Abstract][Full Text] [Related]
20. Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers.
Jiang R; Dong X; Zhu W; Duan Q; Xue Y; Shen Y; Zhang G
PLoS One; 2017; 12(9):e0184338. PubMed ID: 28877268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
